Patents by Inventor Leah M. Gayo

Leah M. Gayo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6686351
    Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-&bgr;. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: February 3, 2004
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Shripad S. Bhagwat, Leah M. Gayo-Fung, Qi Chao
  • Publication number: 20030087901
    Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-&bgr;. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
    Type: Application
    Filed: February 27, 2002
    Publication date: May 8, 2003
    Applicant: Signal Pharmaceuticals, Inc.
    Inventors: Shripad S. Bhagwat, Leah M. Gayo-Fung, Qi Chao
  • Patent number: 6436923
    Abstract: Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-&bgr;. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: August 20, 2002
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Shripad S. Bhagwat, Leah M. Gayo-Fung, Bernd M. Stein, Qi Chao, Anthony R. Gangloff, Jeffrey A. McKie, Kenneth D. Rice
  • Patent number: 6372739
    Abstract: Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, n and p are as defined here. Methods are also disclosed for modulating ER in cells and/or tissues expressing the same, such as bone, breast, prostate, uterus, CNS or the cardiovascular system. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chemicals or natural hormonal imbalances.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: April 16, 2002
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Bernd M. Stein, David Wesley Anderson, Leah M. Gayo-Fung, Mary Doubleday, Graziella I. Shevlin, Adam Kois, Sak Khammungkhune, Ravi Kumar Jalluri, Shripad S. Bhagwat, Jeffrey A. McKie
  • Patent number: 6291456
    Abstract: Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, n and p are as defined here. Methods are also disclosed for modulating ER in cells and/or tissues expressing the same, such as bone, breast, prostate, uterus, CNS or the cardiovascular system. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chemicals or natural hormonal imbalances.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: September 18, 2001
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Bernd M. Stein, David Wesley Anderson, Leah M. Gayo-Fung, May S. Sutherland, Mary Doubleday, Graziella I. Shevlin, Adam Kois, Sak Khammungkhune, Ravi Kumar Jalluri, Shripad S. Bhagwat, Jeffrey A. McKie
  • Patent number: 5935966
    Abstract: Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine-containing compounds and, in one embodiment, are esters of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: August 10, 1999
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Mark J. Suto, Leah M. Gayo, Moorthy S. S. Palanki, Lynn J. Ransone-Fong
  • Patent number: 5932618
    Abstract: Compounds having utility as anti-viral agents in general and, more specifically, to methods for treating a viral condition in an animal are disclosed. The compounds are naphthalene derivatives, and are preferably administered to the patient in the form of a pharmaceutical composition. Viruses treatable by the methods of this invention include viruses of the herpes virus family, such as cytomegalovirus, herpes simplex virus and human lymphotrophic herpes virus.
    Type: Grant
    Filed: November 4, 1996
    Date of Patent: August 3, 1999
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Carla M. Suto, Jun Wu, Leah M. Gayo
  • Patent number: 5852028
    Abstract: Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine-containing compounds and, in one embodiment, are esters of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.
    Type: Grant
    Filed: December 18, 1995
    Date of Patent: December 22, 1998
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Mark J. Suto, Leah M. Gayo, Moorthy S. S. Palanki, Lynn J. Ransone-Fong
  • Patent number: 5811428
    Abstract: Compounds having utility as antinflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine- or pyrazine-containing compounds and, in one embodiment, are carboxyamides of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.
    Type: Grant
    Filed: December 18, 1995
    Date of Patent: September 22, 1998
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Mark J. Suto, Mark E. Goldman, Leah M. Gayo, Lynn J. Ransone-Fong, Moorthy S. S. Palanki, Robert W. Sullivan